AAF TESTING FOR SARS
ALTACHEM PHARMA LTD. INITIATES TESTING BIONEX™ AGAINST CORONAVIRUS
EDMONTON, ALBERTA – Mr. Warren Jackson, President and CEO of Altachem Pharma Ltd., is pleased to announce positive results from testing completed on Bionex™ disinfectant.
To validate the effectiveness of the BionexTM disinfectant formulations, testing has been completed by a Level 3 Bio-Science Laboratory which has received certification through the council for Anti-Microbial Quality (CAQ) in its laboratory accreditation program as well as having memberships with the National Capital Area Regional Society of Quality Assurance (NCARSAQ) and the Society of Quality Assurance (SQA) in the United States.
Based on the positive results received, Altachem has contracted the same laboratory for validation of the lead compound on its viricidal effectiveness specifically against the human coronavirus (believed by some scientists to be SARS).
Thomas Woo, Vice President of Product Development states, “Altachem will continue to take an aggressive approach to proving Bionex™ as a disinfectant for various applications for controlling the coronavirus (believed by some scientists to be SARS) as well as to continue progress for use in blood safety to satisfy the current market demand for this product.”
Altachem will proceed with the necessary steps for regulatory approval to sell BionexTM disinfectant for various applications in the hospital and healthcare settings, such as disinfection for operating rooms, equipment, devices and industrial applications.
Altachem Pharma Ltd. is continuing to evaluate the manufacturing economics of starting another production line in our Shanghai manufacturing facility to produce the Bionex™ disinfectant product for sales in China as well as for export.
Bionex™, a revolutionary product for the potential use in various disinfectant products and potentially inactivates the HIV virus, hepatitis B and C, Herpes and other pathogens in blood products is exclusively licensed to Beijing Altachem Pharma Biotechnology Ltd., as wholly owned foreign enterprise of Altachem Pharma Ltd.
Altachem Pharma Ltd. is a publicly traded (TSX Venture Exchange: AAF), Alberta-based pharmaceutical company committed to the development and commercialization of new pharmaceutical products. The Corporation is developing a multi-tiered, integrated approach for the treatment of HIV/AIDS and cancer using non-toxic therapeutic products and adjunct therapies. The lead products of the Corporation are based on its two proprietary drugs: ACP-HIP and HB. The Corporation's manufacturing facilities located in Edmonton, Alberta and Shanghai, China are certified compliant with internationally recognized quality systems standards.
For additional information, contact:
Roger Andrews, Investor Relations
Altachem Pharma Ltd.
Tel.: (780) 486-8331(Ext. 331)
Toll-free: (877) 502-5939
Fax : (780) 448-1436
E-mail: roger@altachempharma.com
Web site: www.altachempharma.com
Certain information contained in this press release may be forward-looking and is subject to unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct. This is neither an offer to buy or sell a security. For informational purposes only, from sources deemed to be reliable.
“TSX Venture Exchange has neither approved nor disapproved of the information contained herein.”
-30- |
